Combination therapy and drug delivery strategies for treatment of non-alcoholic fatty liver disease

WANG Yanmei; YANG Lei; XIN Xiaofei; YIN Lifang

doi:10.11665/j.issn.1000-5048.20220405

Journal of China Pharmaceutical University > 2022 > 53(4): 423-432. > DOI: 10.11665/j.issn.1000-5048.20220405

WANG Yanmei, YANG Lei, XIN Xiaofei, YIN Lifang. Combination therapy and drug delivery strategies for treatment of non-alcoholic fatty liver disease[J]. Journal of China Pharmaceutical University, 2022, 53(4): 423-432. DOI: 10.11665/j.issn.1000-5048.20220405

Citation:

PDF (1537 KB)

Combination therapy and drug delivery strategies for treatment of non-alcoholic fatty liver disease

1.
Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009
2.
Jiangsu Provincial Engineering Research Center for R&D and Evaluation of Intelligent Drugs and Key Functional Excipients, Nanjing 210009, China

Funds: This study was supported by the National Natural Science Foundation of China (No.81871477)

More Information

Received Date: January 03, 2022
Revised Date: June 06, 2022

Graphical Abstract

Abstract

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a series of chronic liver diseases strongly associated with the metabolic disorder with an increasing rate of worldwide prevalence.Due to its complicated pathogenesis, only Saroglitazar has been approved by Indian Drug Controller General (DCGI) as a PPAR-α/γ dual agonist to treat non-cirrhotic non-alcoholic steatohepatitis.Combination therapy, which can target same or different signaling pathways of NAFLD pathogenesis, has been developed to achieve synergistic therapeutic efficacy.Currently, small-molecule drug combination, RNAi combination therapy, and chemogene therapy are proposed as promising strategies in NAFLD treatment.In addition, designing a smart, safe and effective drug delivery system is key to realizing the druggability, clinical translation and industrialization of small molecule drugs and gene drugs.This review summarizes the research status and delivery system of small-molecule drug combination, RNAi combination therapy, and chemogene therapy, in the hope of providing some novel insight for the treatment of NAFLD.
- non-alcoholic fatty liver disease,
- liver fibrosis,
- combination therapy,
- chemogene therapy,
- targeting strategy

FullText(HTML)

References (48)

References

[1]	. J Hepatol，2019，70（3）：531-544.
[2]	Guo YT，Chen J，Liu N，et al. Association of circulating TXNIP levels with fatty liver in newly diagnosed type 2 diabetes mellitus［J］. Diabetes Metab Syndr Obes，2022，15：225-233.
[3]	Sodum N，Kumar G，Bojja SL，et al. Epigenetics in NAFLD/NASH：targets and therapy［J］. Pharmacol Res，2021，167：105484.
[4]	Rives C，Fougerat A，Ellero-Simatos S，et al. Oxidative stress in NAFLD：role of nutrients and food contaminants［J］. Biomolecules，2020，10（12）：1702.
[5]	Safari Z，Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease （NAFLD）［J］. Cell Mol Life Sci，2019，76（8）：1541-1558.
[6]	Ahrari A，Najafzadehvarzi H，Taravati A，et al. The inhibitory effect of PLGA-encapsulated berberine on hepatotoxicity and α-smooth muscle actin （α-SMA） gene expression［J］. Life Sci，2021，284：119884.
[7]	Juanola O，Martínez-López S，Francés R，et al. Non-alcoholic fatty liver disease：metabolic，genetic，epigenetic and environmental risk factors［J］. Int J Environ Res Public Health，2021，18（10）：5227.
[8]	Prikhodko VA，Bezborodkina NN，Okovityi SV. Pharmacotherapy for non-alcoholic fatty liver disease：emerging targets and drug candidates［J］. Biomedicines，2022，10（2）：274.
[9]	Dufour JF，Caussy C，Loomba R. Combination therapy for non-alcoholic steatohepatitis：rationale，opportunities and challenges［J］. Gut，2020，69（10）：1877-1884.
[10]	B?ttger R，Pauli G，Chao PH，et al. Lipid-based nanoparticle technologies for liver targeting［J］. Adv Drug Deliv Rev，2020，154/155：79-101.
[11]	Peng W，Cheng SM，Bao ZH，et al. Advances in the research of nanodrug delivery system for targeted treatment of liver fibrosis［J］. Biomed Pharmacother，2021，137：111342.
[12]	Tacke F. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis［J］. Expert Opin Investig Drugs，2018，27（3）：301-311.
[13]	Radun R，Trauner M. Role of FXR in bile acid and metabolic homeostasis in NASH：pathogenetic concepts and therapeutic opportunities［J］. Semin Liver Dis，2021，41（4）：461-475.
[14]	Kumar V，Xin XF，Ma JY，et al. Therapeutic targets，novel drugs，and delivery systems for diabetes associated NAFLD and liver fibrosis［J］. Adv Drug Deliv Rev，2021，176：113888.
[15]	Ratziu V，Sanyal A，Harrison SA，et al. Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis：final analysis of the phase 2b CENTAUR study［J］. Hepatology，2020，72（3）：892-905.
[16]	Pedrosa M，Seyedkazemi S，Francque S，et al. A randomized，double-blind，multicenter，phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis：study design of the TANDEM trial［J］. Contemp Clin Trials，2020，88：105889.
[17]	Griggs LA，Hassan NT，Malik RS，et al. Fibronectin fibrils regulate TGF-β1-induced epithelial-mesenchymal transition［J］. Matrix Biol，2017，60/61：157-175.
[18]	Kumar V，Dong YX，Kumar V，et al. The use of micelles to deliver potential hedgehog pathway inhibitor for the treatment of liver fibrosis［J］. Theranostics，2019，9（25）：7537-7555.
[19]	Kumar V，Mundra V，Mahato RI. Nanomedicines of hedgehog inhibitor and PPAR-γ agonist for treating liver fibrosis［J］. Pharm Res，2014，31（5）：1158-1169.
[20]	Romualdo GR，da Silva TC，de Albuquerque Landi MF，et al. Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease［J］. Environ Toxicol，2021，36（2）：168-176.
[21]	Ma R，Chen J，Liang YL，et al. Sorafenib：a potential therapeutic drug for hepatic fibrosis and its outcomes［J］. Biomed Pharmacother，2017，88：459-468.
[22]	Chen Y，Liu YC，Sung YC，et al. Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors［J］. Sci Rep，2017，7：44123.
[23]	Sung YC，Liu YC，Chao PH，et al. Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development［J］. Theranostics，2018，8（4）：894-905.
[24]	Shafie F，Nabavizadeh F，Shafie Ardestani M，et al. Sorafenib-loaded PAMAM dendrimer attenuates liver fibrosis and its complications in bile-duct-ligated rats［J］. Can J Physiol Pharmacol，2019，97（8）：691-698.
[25]	Keating GM. Sorafenib：a review in hepatocellular carcinoma［J］. Target Oncol，2017，12（2）：243-253.
[26]	Qin LF，Qin JM，Zhen XM，et al. Curcumin protects against hepatic stellate cells activation and migration by inhibiting the CXCL12/CXCR4 biological axis in liver fibrosis：a study in vitro and in vivo［J］. Biomed Pharmacother，2018，101：599-607.
[27]	Lung YM，Man FY，Christian S，et al. ARO-HSD，an investigational RNAi therapeutic，demonstrates reduction in ALT and hepatic HSD17B13 mRNA and protein in patients with NASH or suspected NASH［R］. AASLD，2021. https：//www.natap.org/2021/AASLD/AASLD_99.htm.
[28]	Cui H，Zhu XY，Li SY，et al. Liver-targeted delivery of oligonucleotides with N-acetylgalactosamine conjugation［J］. ACS Omega，2021，6（25）：16259-16265.
[29]	Ji D，Wang QH，Zhao Q，et al. Co-delivery of miR-29b and germacrone based on cyclic RGD-modified nanoparticles for liver fibrosis therapy［J］. J Nanobiotechnology，2020，18（1）：86.
[30]	Yu FJ，Chen BC，Dong PH，et al. HOTAIR epigenetically modulates PTEN expression via microRNA-29b：a novel mechanism in regulation of liver fibrosis［J］. Mol Ther，2017，25（1）：205-217.
[31]	Zeng CX，Wang YL，Xie C，et al. Identification of a novel TGF-β-miR-122-fibronectin 1/serum response factor signaling cascade and its implication in hepatic fibrogenesis［J］. Oncotarget，2015，6（14）：12224-12233.
[32]	Li J，Ghazwani M，Zhang YF，et al. miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression［J］. J Hepatol，2013，58（3）：522-528.
[33]	Wu J，Huang JS，Kuang SC，et al. Synergistic microRNA therapy in liver fibrotic rat using MRI-visible nanocarrier targeting hepatic stellate cells［J］. Adv Sci （Weinh），2019，6（5）：1801809.
[34]	Zhao Z，Li YK，Jain A，et al. Development of a peptide-modified siRNA nano complex for hepatic stellate cells［J］. Nanomedicine，2018，14（1）：51-61.
[35]	Qiao JB，Fan QQ，Zhang CL，et al. Hyperbranched lipoid-based lipid nanoparticles for bidirectional regulation of collagen accumulation in liver fibrosis［J］. J Control Release，2020，321：629-640.
[36]	Boakye CHA，Patel K，Doddapaneni R，et al. Novel amphiphilic lipid augments the co-delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment［J］. J Control Release，2017，246：120-132.
[37]	Gong CN，Hu CL，Gu FF，et al. Co-delivery of autophagy inhibitor ATG7 siRNA and docetaxel for breast cancer treatment［J］. J Control Release，2017，266：272-286.
[38]	Zhang BF，Xing L，Cui PF，et al. Mitochondria apoptosis pathway synergistically activated by hierarchical targeted nanoparticles co-delivering siRNA and lonidamine［J］. Biomaterials，2015，61：178-189.
[39]	Shrestha B，Wang LJ，Brey EM，et al. Smart nanoparticles for chemo-based combinational therapy［J］. Pharmaceutics，2021，13（6）：853.
[40]	Salvoza N，Giraudi PJ，Tiribelli C，et al. Natural compounds for counteracting nonalcoholic fatty liver disease （NAFLD）：advantages and limitations of the suggested candidates［J］. Int J Mol Sci，2022，23（5）：2764.
[41]	Jia JD，Bauer M，Cho JJ，et al. Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen α1（I） and TIMP-1［J］. J Hepatol，2001，35（3）：392-398.
[42]	Song IS，Nam SJ，Jeon JH，et al. Enhanced bioavailability and efficacy of silymarin solid dispersion in rats with acetaminophen-induced hepatotoxicity［J］. Pharmaceutics，2021，13（5）：628.
[43]	Qiao JB，Fan QQ，Xing L，et al. Vitamin A-decorated biocompatible micelles for chemogene therapy of liver fibrosis［J］. J Control Release，2018，283：113-125.
[44]	Jung Y，Brown KD，Witek RP，et al. Accumulation of hedgehog-responsive progenitors parallels alcoholic liver disease severity in mice and humans［J］. Gastroenterology，2008，134（5）：1532-1543.
[45]	Kumar V，Mondal G，Dutta R，et al. Co-delivery of small molecule hedgehog inhibitor and miRNA for treating liver fibrosis［J］. Biomaterials，2016，76：144-156.
[46]	Han J，He YP，Zhao H，et al. Hypoxia inducible factor-1 promotes liver fibrosis in nonalcoholic fatty liver disease by activating PTEN/p65 signaling pathway［J］. J Cell Biochem，2019，120（9）：14735-14744.
[47]	Hong F，Tuyama A，Lee TF，et al. Hepatic stellate cells express functional CXCR4：role in stromal cell-derived factor-1alpha-mediated stellate cell activation［J］. Hepatology，2009，49（6）：2055-2067.
[48]	Liu CH，Chan KM，Chiang T，et al. Dual-functional nanoparticles targeting CXCR4 and delivering antiangiogenic siRNA ameliorate liver fibrosis［J］. Mol Pharm，2016，13（7）：2253-2262.

[1]	YANG Nan, ZHANG Xiao, LYU Hui, HUO Meirong, XU Wei. Advances in immune checkpoint inhibitors combined with other treatments[J]. Journal of China Pharmaceutical University, 2023, 54(2): 131-140. DOI: 10.11665/j.issn.1000-5048.20221028002
[2]	YAO Zheng, LI Zihan, GAO Liming, HU Xing, CHEN Yan, PAN Wenqi, LI Qian. Advances of research on CAR-T cell immunotherapy for solid tumors[J]. Journal of China Pharmaceutical University, 2021, 52(4): 496-504. DOI: 10.11665/j.issn.1000-5048.20210413
[3]	BU Hong, ZHOU Jinpei, ZHANG Huibin. Research progress of mitogen-activated protein kinase interacting kinases inhibitors in tumor immunotherapy[J]. Journal of China Pharmaceutical University, 2021, 52(4): 410-421. DOI: 10.11665/j.issn.1000-5048.20210403
[4]	CHEN Wenting, LIU Jun. Advances in research on immune checkpoint and its inhibitors in glioma[J]. Journal of China Pharmaceutical University, 2021, 52(1): 104-112. DOI: 10.11665/j.issn.1000-5048.20210115
[5]	XING Xuyang, WANG Xiaochun, HE Wei. Advances in research on tumor immunotherapy and its drug development[J]. Journal of China Pharmaceutical University, 2021, 52(1): 10-19. DOI: 10.11665/j.issn.1000-5048.20210102
[6]	LI Fang, XIN Junbo, SHI Qin, MAO Chengqiong. Advances in near infrared photoimmunotherapy of tumor[J]. Journal of China Pharmaceutical University, 2020, 51(6): 664-674. DOI: 10.11665/j.issn.1000-5048.20200604
[7]	TIAN Jiping, ZHANG Jian, ZHOU Jinpei, ZHANG Huibin. Advances in small molecule inhibitors of PD-1/PD-L1 immune checkpoint pathway[J]. Journal of China Pharmaceutical University, 2019, 50(1): 1-10. DOI: 10.11665/j.issn.1000-5048.20190101
[8]	ZHANG Rui, JIANG Tao, ZENG Tianzhu, YAO Wenbing, GAO Xiangdong, TIAN Hong. Advances of combined immunotherapy in tumor[J]. Journal of China Pharmaceutical University, 2018, 49(4): 383-391. DOI: 10.11665/j.issn.1000-5048.20180401
[9]	YANG Ruocong, DUAN Feipeng, CHAO Jiahong, TIAN Pengpeng, YAN Zhiyong, LI Shaojing. Advances of microRNA activity in innate immunity[J]. Journal of China Pharmaceutical University, 2017, 48(4): 396-406. DOI: 10.11665/j.issn.1000-5048.20170403
[10]	LIU Kejun, ZHANG Zhimin, RAN Ting, CHEN Hongli, LU Tao, CHEN Yadong. Advances in BET bromodomain protein inhibitors[J]. Journal of China Pharmaceutical University, 2015, 46(3): 264-271. DOI: 10.11665/j.issn.1000-5048.20150302

Cited By

Get Citation

PDF

XML

Article views (214) PDF downloads (576)

Turn off MathJax

Article Contents

Abstract

References

Combination therapy and drug delivery strategies for treatment of non-alcoholic fatty liver disease

Abstract

References

Related Articles

Catalog

Combination therapy and drug delivery strategies for treatment of non-alcoholic fatty liver disease

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content